// App-Quantinova.ai

311 2014 HTN : Early Losartan Treatment Prevents the Developmental Programming of Cardiac Dysfunction Caused by Neonatal High Oxygen Exposure in Rats

Researchers

Presenter

  • Sarah Beland-Bonenfant

Principal Investigators

  • Anne Dios

  • Daniela R Dartora

  • Marie-Amelie Lukaszewski

  • Anik Cloutier

  • Megan Sutherland

  • Denis DeBlois

  • Pierre Paradis

  • Ernesto L Schiffrin

  • Anne Monique Nuyt

Medical Centers

  • CHU Sainte-Justine, Montreal, QC, Canada

  • McGill Univ, Jewish General Hosp, Lady Davis Inst for Medical Res, Montreal, QC, Canada

  • University of Montreal, Montreal, QC, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Endocrine/metabolic Diseases (ME)

Disease

  • Infant Respiratory Distress Syndrome

  • Congestive heart failure

  • Hypertrophic cardiomyopathy

  • Diabetic retinopathy

Biomarkers

  • Solute Carrier Family 33 Member 1

Drug/Treatment

  • Angiotensin II

  • Lorestan

Outcome

  • N/A

Study Design

  • N/A

Phase

  • NA

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • Interim

Copyright © 2026. QuantiNova All rights reserved